Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on April 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $463.5M gross proceeds from 7.475M shares at $62.00, including fully exercised 975,000-share option.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $463.5M gross proceeds from 7.475M shares at $62.00, including fully exercised 975,000-share option
- Capital funds inflammatory bowel disease and rheumatic disease programs, including clinical trials and Phase 3 readiness
- Equity financing strengthens development runway but creates approximately 7.475M shares of dilution
- Offering closed April 16, 2026 under an effective Form S-3 shelf registration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.